Serious science. Disciplined capital. Long horizons.
We are interested in problems that matter, technologies that can change the constraints, and entrepreneurs with the judgment to turn hard evidence into practical progress.
From mechanism to milestones
- 1Start with the mechanism
Understand the scientific claim and what must be true for it to work.
- 2Design the evidence
Identify the decisive experiments, clinical outcomes, deployment metrics and milestones.
- 3Underwrite reality
Model capital intensity, timing, risk, competitive alternatives and commercial adoption.
- 4Build with people
Help founders with scientific, operational, institutional and financing challenges where our involvement is genuinely useful.
- 5Think in cycles
Capital requirements and proof points differ between preventive health, therapeutics, infrastructure and enabling technologies. Strategies must reflect those differences.
The Wytham Test
Six questions we ask of every company and every strategy. They do not remove uncertainty. They make it explicit, and they make it easier to say no to projects that are scientifically interesting but not ready.
- 1
Consequence
Would solving this problem matter materially in ten to twenty years?
A large addressable market is not a substitute for an important problem.
- 2
Scientific depth
Is the advantage grounded in a difficult-to-replicate mechanism, discovery, dataset, manufacturing capability or systems insight?
Novelty alone does not make a business.
- 3
Proof
What result would disprove the thesis, and what independently verifiable evidence supports or challenges it?
If no negative answer is possible, we are telling ourselves a story.
- 4
Commercial reality
Who benefits, who pays, and why can adoption or deployment scale?
A credible buyer and a credible route to adoption, named before we invest.
- 5
Capital discipline
Can milestones, ownership, pricing, reserves and a realistic exit or durable cash-flow model justify the risk?
A company can be scientifically right and still fail if it is financed for the wrong milestones.
- 6
Integrity
Are the incentives, governance, scientific claims and societal consequences defensible?
A good strategic idea is never a reason to loosen governance.
Patient capital is still accountable capital
Long time horizons do not make an opportunity a better investment. They make poor decisions more expensive. Our answer is to understand what must be proved at each stage, match the capital to that work, and remain willing to stop when the evidence no longer supports the thesis.
Wanting an outcome to exist is not the same as wanting to own an asset at any price. Entry valuation, ownership, follow-on requirements, dilution and realistic routes to liquidity are part of every decision, and the cost of reaching the next useful proof point matters as much as the size of the opportunity.
Capital is a beginning, not the whole work
Original research and writing on the fields we follow, published so that our reasoning can be examined.
Practised nowMilestone-based capital for differentiated science, beginning with longevity and regenerative medicine.
In formationSelective venture creation where important science has no natural commercial home.
As capability is builtPartnerships and further strategies, entered only where expertise and evidence justify them.
Long-termHow the institution can expand
Two dimensions: the frontiers we study, and the forms of capital and company building each may eventually need. Most of this grid is deliberately empty. Cells fill only as teams, evidence and vehicles exist.
| Capability | Human Life | Human Capability | Planetary Foundations | Enabling Intelligence & Industry |
|---|---|---|---|---|
| Research and perspectives | Publishing | Writing | Writing | Writing |
| Early-stage venture | In formation | Exploring | Not yet | Not yet |
| Company creation | Exploring | Not yet | Not yet | Not yet |
| Growth capital | Not yet | Not yet | Not yet | Not yet |
| Infrastructure capital | Not yet | Not yet | Not yet | Not yet |
No vehicle shown here is open for investment. “In formation” describes work under way, not a launched fund. Any future strategy will be subject to applicable legal, regulatory and governance requirements.
Governance before scale
Different activities can share a philosophy without sharing a balance sheet, an investment committee or the same obligations to investors. Keeping related-party transactions, ownership interests and fiduciary duties clear matters most when an investment platform also helps form companies or works with clinical operators.
Permanence cannot be created by naming something permanent. It comes from keeping talented people, building a culture in which scientific and investment judgments can be challenged, learning from mistakes, and treating partners fairly over time.